The Blueprint Goes Agentic — AI in Protocol Design & Trial Simulation
Summary
An executive read on five vendors rebuilding protocol design and trial simulation with AI — QuantHealth for in-silico trial simulation and Katina protocol scoring, Biorce for the Aika protocol-design platform after its Series A, Faro for structured, machine-readable protocols and its Bristol Myers Squibb system-of-record collaboration, Cytel for adaptive-design statistics with East Horizon and an AI code assistant, and Evinova, AstraZeneca's Study Designer platform, now partnering with Astellas, Bristol Myers Squibb and Merck KGaA.
For market education, not a buying recommendation. The full issue is in the PDF.
Choosing between vendors like these?
Vendor advisory looks at workflow fit, vendor evidence, enterprise readiness and regulated-use controls.
Not sure where to start?
The AI assessment helps you pick the workflows worth changing first. See selected work for what that looks like.
